Dmitry Balyasny’s Cymabay Therapeutics CBAY Stock Holding History

Dmitry Balyasny’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,024,139	Closed	-$15.3M	–	3008
2023 Q3	$15.3M	Sell	1,024,139 -690,679	-40%	-$9.16M	0.03%	687
2023 Q2	$18.8M	Sell	1,714,818 -242,250	-12%	-$2.26M	0.04%	555
2023 Q1	$17.1M	Buy	1,957,068 +1,901,769	+3,439%	+$15.2M	0.04%	579
2022 Q4	$347K	Buy	+55,299	New	+$210K	﹤0.01%	1950
2019 Q3	–	Sell	-80,264	Closed	-$575K	–	1697
2019 Q2	$575K	Buy	80,264 +27,017	+51%	+$306K	﹤0.01%	1199
2019 Q1	$707K	Sell	53,247 -190,819	-78%	-$2.03M	﹤0.01%	1108
2018 Q4	$1.92M	Buy	+244,066	New	+$2.32M	0.01%	727
2015 Q4	–	Sell	-12,600	Closed	-$24K	–	1498
2015 Q3	$24K	Sell	12,600 -1,715	-12%	-$4.67K	﹤0.01%	1111
2015 Q2	$39K	Buy	+14,315	New	+$58.8K	﹤0.01%	1109

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dmitry Balyasny's CBAY Position: Q4 2023 in Review

Dmitry Balyasny sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 1,024,139 shares — an estimated $15.3M sold.

Dmitry Balyasny first reported a position in CBAY in Q2 2015 and held it in 9 quarters. The position peaked at $18.8M in Q2 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Dmitry Balyasny reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Dmitry Balyasny sold 1,024,139 Cymabay Therapeutics shares in Q4 2023, an estimated $15.3M.
Dmitry Balyasny first reported a position in Cymabay Therapeutics in Q2 2015 and held it in 9 quarters.
Dmitry Balyasny's Cymabay Therapeutics position peaked at $18.8M in Q2 2023.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.